Neion Bio raises USD 23m Series A to scale egg-based bio-manufacturing. June 12, 2026 New York-based Neion Bio, Inc., a biotechnology company developing a genetic engineering-based platform for biologics manufacturing, has closed an oversubscribed USD 23 million Series A financing round to advance its Raptor platform and expand a pipeline spanning biosimilars, innovative medicines, critical reagents, and animal health. The Neion Bio Series A funding positions the company to accelerate a manufacturing approach it argues could materially reduce the cost and capital intensity of producing complex biologic medicines. The round was led by Caffeinated Capital, an early backer of the company, with participation from new investors Digitalis Ventures, Ensemble VC, and Trust Ventures, alongside follow-on investment from existing backers Haystack and Basis Set Ventures, among others. The company said proceeds will fund pipeline expansion and continued development of proprietary technologies designed to enable biologics production at meaningful scale within days - a timeline the company says would enable faster iteration cycles for screening and production of novel molecules. Neion Bio's central premise is that the chicken egg, refined over hundreds of millions of years of evolution and centuries of selective breeding, represents an underutilized production system for complex therapeutic proteins. The company's Raptor platform uses precision genome engineering - made possible by recent advances in avian primordial germ cell (PGC) biology and large genomic datasets - to restrict recombinant protein expression to the egg itself. The result, the company said, is a sterile, self-contained, naturally high-yield vessel that sidesteps the capital-intensive bioreactor infrastructure associated with conventional mammalian cell culture manufacturing. The scientific rationale is that eggs already produce and stabilise large quantities of protein in a controlled biological environment. By engineering the genome of the laying hen rather than building industrial steel tanks or maintaining complex disposable plastic systems, Neion argues it can achieve consistent protein expression with simplified operations and a manufacturing footprint that is both more resilient and more cost-efficient than traditional approaches. The platform is said to be particularly suited to complex, glycosylated proteins that have proven difficult to express using conventional methods - a category that includes many high-value biologics currently on the market or in development. The approach places Neion in a distinct segment of the biologics manufacturing landscape. Traditional contract development and manufacturing organisations rely on Chinese hamster ovary (CHO) cell culture as the dominant production system for monoclonal antibodies and related biologics. Transgenic avian platforms have been explored previously - including by companies such as Synageva BioPharma, which produced sebelipase alfa in eggs before its 2015 acquisition by Alexion - but Neion's founders argue that advances in precision genome engineering now make the approach substantially more tractable and scalable than earlier iterations. Prior commercial traction and team build-out. The Series A follows a period of deliberate platform and team development since the company's founding in 2024. Neion launched with approximately USD 11 million in financing from a consortium led by Caffeinated Capital with significant participation from Basis Set Ventures and Haystack VC. When the company emerged from stealth earlier this year, it simultaneously announced its first commercial co-development and supply agreement with an undisclosed major pharmaceutical company, covering the development and commercialisation of up to three monoclonal antibodies. That deal, structured to include upfront and milestone payments along with profit-sharing on commercialised products, provided early validation of the Raptor(TM) platform's commercial applicability to the biosimilars market. In April 2026, Neion appointed James Kehler, VMD, PhD, as Head of Avian Sciences. Kehler joined from Colossal Biosciences, where he served as Vice President of BioSynergy. His work in cloning mammals from blood was recognised by TIME magazine as one of the best inventions of 2025. The appointment followed the earlier recruitment of Chief Scientific Officer Dr. Sven Bocklandt, also from Colossal Biosciences, where he directed genetic engineering efforts central to the company's de-extinction programs. Both hires reflect a deliberate strategy of recruiting scientists with frontier genome engineering expertise into the platform's technical leadership. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Neion Bio has raised $23 million in an oversubscribed Series A round led by Caffeinated Capital to advance its biologics manufacturing platform. The company is developing the Raptor platform, which uses genetically engineered chicken eggs to produce recombinant proteins. The platform leverages eggs as biological vessels, restricting protein production to the egg itself through precision genetic engineering. Neion Bio aims to address challenges in biologics manufacturing, including securing domestic supply chains and access to critical medicines. Co-founder and CEO Dimi Kellari said advances in foundational engineering tools are enabling the company to unlock what he called the next bioindustrial revolution. The funding will support platform advancement and pipeline expansion.